Meeting
2016 ASCO Annual Meeting
Patient-derived tumor xenografts in humanized NSG-SGM3 mice: a new immuno-oncology platform.
Authors
Li-Chin Yao
The Jackson Laboratory, Sacramento, CA
Li-Chin Yao , Jonathan Riess , Mingshan Cheng , Minan Wang , Jacques Banchereau , Lenny Shultz , Karolina Palucka , James G. Keck
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics and Translational Research
Sub Track
Immune Checkpoint Inhibitors
Citation
J Clin Oncol 34, 2016 (suppl; abstr 3074)
DOI
10.1200/JCO.2016.34.15_suppl.3074
Abstract #
3074
Poster Bd #
396
Abstract Disclosures
Similar Posters
Poster
2017 Genitourinary Cancers Symposium
Humanized mice (humice) carrying patient-derived xenograft (PDX) as a platform to develop immunotherapy in bladder cancer (BCa).
First Author: Chong-xian Pan
Poster
2023 ASCO Breakthrough
Efficacy of PD-1 inhibitors in the treatment of advanced gastrointestinal tumors and the effect on T-lymphocyte subsets and IL-6 levels in patients.
First Author: XinCheng He
Poster
2023 ASCO Annual Meeting
An open-label clinical trial of RP2 and RP3 oncolytic immunotherapy in combination with atezolizumab and bevacizumab for the treatment of patients with advanced colorectal carcinoma.
First Author: Dale Randall Shepard
Poster
2021 ASCO Annual Meeting
Update on safety and efficacy of a phase 1/2 of SNS-301 added to pembrolizumab in patients with advanced squamous cell carcinoma of the head and neck (SCCHN).
First Author: Alain Patrick Algazi